Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.75 |
| ▸ | BTK | Q06187 | 3/20 | 0.75 |
| ▸ | JAK2 | O60674 | 1/20 | 0.75 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.75 |
| ▸ | ROS1 | P08922 | 1/20 | 0.75 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.75 |
| ▸ | FLT3 | P36888 | 1/20 | 0.75 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.75 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.75 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.75 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Entospletinib SCHEMBL29355138 | 0.86 | SYK (1.00) | SYKBTKJAK2NTRK1ROS1 | |
| SCHEMBL25290866 | 0.86 | SYK (0.75) | SYKBTKJAK2NTRK1ROS1 | |
| Entospletinib SCHEMBL2483776 | 0.86 | SYK (1.00) | SYKBTKJAK2NTRK1ROS1 | |
| SCHEMBL30299448 | 0.86 | SYK (0.75) | SYKBTKJAK2NTRK1ROS1 | |
| SCHEMBL2481484 | 0.85 | SYK (0.72) | SYKBTKJAK2NTRK1ROS1 | |
| SCHEMBL2481530 | 0.83 | SYK (1.00) | SYKBTKJAK2NTRK1ROS1 | |
| Entospletinib SCHEMBL19283440 | 0.83 | SYK (0.89) | SYKBTKJAK2NTRK1ROS1 | |
| Entospletinib SCHEMBL23777555 | 0.83 | SYK (0.89) | SYKBTKJAK2NTRK1ROS1 | |
| SCHEMBL30299547 | 0.82 | SYK (0.73) | SYKBTKJAK2NTRK1ROS1 | |
| SCHEMBL25292732 | 0.82 | SYK (0.73) | SYKBTKJAK2NTRK1ROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277293-A1 | POLYMORPHS OF SYK INHIBITORS | Kronos Bio, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-9949932-B2 | Formulation of syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9918939-B2 | Formulation of Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20180071302-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-9707236-B2 | Combination methods for treating cancers | GILEAD SCIENCES, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170020821-A1 | FORMULATION OF SYK INHIBITORS | Kronos Bio, Inc. | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020821-A1 | FORMULATION OF SYK INHIBITORS | SYK, BTK, LYN | SYK 1/4885BTK 2/4885JAK2 12/4885 |
| US-20200277293-A1 | POLYMORPHS OF SYK INHIBITORS | SYK, BTK, ZAP70 | SYK 1/4885BTK 2/4885JAK2 60/4885 |
| US-20180071302-A1 | SYK INHIBITORS | SYK, BTK, LYN | SYK 1/4885BTK 2/4885JAK2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.